Relationship between Plasma Lipid Profile and Cognitive Status in Early Alzheimer Disease

Autores de IIS La Fe

• María Del Carmen Peña Bautista

  Autor

• Lourdes Álvarez Sánchez

  Autor

• Gemma María García Lluch

  Autor

• Luis Raga Rodríguez

  Autor

• Paola Claudia Del Valle Quevedo

  Autor

• Mar Pereto Pamblanco

  Autor

• 

  Miguel Baquero Toledo

  Autor

• 

  María Consuelo Cháfer Pericás

  Autor

Participantes ajenos a IIS La Fe

• Balaguer, A

Grupos

• Grupo de Investigación en Enfermedad de Alzheimer (GINEA)

Abstract

Alzheimer disease (AD) is a heterogeneous and complex disease in which different pathophysiological mechanisms are involved. This heterogenicity can be reflected in different atrophy patterns or clinical manifestations. Regarding biochemical pathways involved in early AD, lipid metabolism plays an important role; therefore, lipid levels have been evaluated as potential AD diagnosis biomarkers, and their levels could be related to different AD clinical manifestations. Therefore, the aim of this work is to study AD lipid profiles from early AD patients and evaluate their clinical significance. For this purpose, untargeted plasma lipidomic analysis was carried out in early AD patients (n = 31) diagnosed with cerebrospinal fluid (CSF) biomarkers. Cluster analysis was carried out to define early AD subgroups according to the lipid levels. Then, the clinical significance of each lipid profile subgroup was studied, analyzing differences for other variables (cognitive status, CSF biomarkers, medication, comorbidities, age, and gender). The cluster analysis revealed two different groups of AD patients. Cluster 1 showed higher levels of plasma lipids and better cognitive status than Cluster 2. However, no differences were found for the other variables (age, gender, medication, comorbidities, cholesterol, and triglycerides levels) between both groups. Plasma lipid levels could differentiate two early AD subgroups, which showed different cognitive statuses. However, further research with a large cohort and longitudinal study evaluating the clinical evolution of these patients is required. In general, it would involve a relevant advance in the knowledge of AD pathological mechanisms, potential treatments, and precision medicine.

Keywords

• Alzheimer; lipidomics; plasma; subtypes; cognitive status